RUBICON · Rubicon Research Ltd · Biotechnology & Drugs
RUBICON · Rubicon Research Ltd · Biotechnology & Drugs
As of 06 Nov close
52-week range
13.1% below 52-week high
52-week range: as of 06 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 52 days old
Revenue (latest Q)
₹534 Cr
Revenue YoY
PAT YoY
+95.8%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
24.7
P/S (TTM)
15.7
Sector P/E
36.3
Dividend yield
0.0%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| RUBICON (this stock) | 79.1 | 24.7 | +14.9% | +22.4% | 0.24 | 0.0% |
| Sun Pharmaceutical Industries | 38.4 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 72.7 | 19.2 | +15.3% | +27.1% | 141.16 | +0.8% |
Promoter
falling 2q
FII
stable
MF
7.23% (+0.09pp)
rising 3q
Insider trades
| Date | Insider | Type | Qty | Value |
|---|---|---|---|---|
| 11 Sept 2026 | GIRISH SUBRAMANIAM IYER | SELL | 3,000 | ₹54.89 lakh |
| 10 Sept 2026 | GIRISH SUBRAMANIAM IYER | SELL | 1,296 | ₹23.18 lakh |
| 09 Sept 2026 | GIRISH SUBRAMANIAM IYER | SELL | 1,500 | ₹27.32 lakh |
| 08 Sept 2026 | GIRISH SUBRAMANIAM IYER | SELL | 1,000 | ₹18.1 lakh |
| 28 Aug 2026 | Vinayak Sawant | SELL | 1,100 | ₹20.28 lakh |
| 28 Aug 2026 | Vinayak Sawant | SELL | 1,100 | ₹20.28 lakh |
| 18 Aug 2026 | Sarabjit Singh | SELL | 35,000 | ₹1,773 |
| 30 Jun 2026 | Girish Subramaniam Iyer | SELL | 10,000 | ₹1,407 |
| 29 Jun 2026 | Prakash Chandran | SELL | 10,000 | ₹1.41 Cr |
| 29 Jun 2026 | Prakash Chandran | SELL | 10,000 | ₹1.41 Cr |
| 29 Jun 2026 | Prakash Chandran | SELL | 20,000 | ₹2.82 Cr |
| 29 Jun 2026 | Prakash Chandran | SELL | 20,000 | ₹2.82 Cr |
| 26 Jun 2026 | Prakash Chandran | SELL | 20,000 | ₹2.82 Cr |
| 26 Jun 2026 | Prakash Chandran | SELL | 20,000 | ₹2.82 Cr |
| 17 Jun 2026 | DINESH BHASKAR RAJADHYAX | SELL | 2,282 | ₹1,363 |
| 12 Jun 2026 | Vinayak Sawant | SELL | 780 | ₹1,292 |
| 11 Jun 2026 | Vinayak Sawant | SELL | 1,400 | ₹1,281 |
| 11 Jun 2026 | Rajendra Mhaske | SELL | 3,000 | ₹1,257 |
| 10 Jun 2026 | Vinayak Sawant | SELL | 600 | ₹1,192 |
| 10 Jun 2026 | Rajendra Mhaske | SELL | 1,000 | ₹1,203 |
Bulk/block deals
| date | canonicalSymbol | buy quantity | buyer count | deal strength | deal types present |
|---|---|---|---|---|---|
| 2026-08-26 | RUBICON | 843372 | 1 | WEAK | BULK |
News timeline
- mediumbusiness-standard.com· 03 Nov 2026, 11:43 pmThe tide is turning: Smallcap AI winners are now facing a valuation test
- unknowneconomictimes.indiatimes.com· 27 Aug 2026, 09:59 amUp to 407% returns! 12 recently listed stocks turn multibaggers as Nifty IPO index hits 52-week high
Concalls & investor presentations
AI-generatedKey takeaway: Rubicon Research Limited reported strong Q1 FY2026-27 results, with revenue from operations at INR534 crores, a 51% year-on-year growth. EBITDA reached INR131 crores, up 65%, and PAT was INR85 crores, up 95% compared to the previous year. The Arinna acquisition, completed in April 2026, contributed approximately INR12 crores to revenue but had no material impact on EBITDA. The company highlighted a 36% ROCE for the quarter, despite a significant portion of capital employed being in pre-revenue investments. Gross margins improved sequentially to 67.7%, despite rising input and freight costs. Management noted tactical measures to prioritize gross margins by exiting lower-margin businesses, which led to a marginal sequential drop in USD revenue but improved margins. The company acquired a manufacturing facility in New Jersey, USA, through a court-supervised bankruptcy process for USD2.9 million, enhancing its US manufacturing footprint. The Pithampur facility in India is expected to ramp up commercial operations in Q1 2027. R&D expenses were 10.9% of revenue, with a 3.3x R&D productivity ratio. Management emphasized a portfolio-based approach to R&D and manufacturing, focusing on risk diversification and capacity expansion. The CFO, Nitin Jajodia, is transitioning to Chief Commercial Officer, with Rohit assuming the CFO role. The company expects continued growth in specialty products and is preparing for future phases of the Arinna acquisition, focusing first on growth levers and later on profitability.
The document emphasizes strong financial performance, operational improvements, and strategic expansions, reflecting a positive tone.
Sourced from an exchange-filed transcript, dated 19 Aug 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Rubicon Research Limited's investor presentation dated August 14, 2026, provided a comprehensive overview of the company's financial performance for Q1 FY 2026-27. The presentation reported a 51.6% year-on-year increase in revenue from operations, amounting to ₹5,343 million, with EBITDA rising to ₹1,312 million. The company highlighted the impact of the Arinna acquisition, contributing ₹128 million to revenue. Management noted a stable pricing environment and strong revenue visibility, with USD revenue reaching $55 million, up 32% year-on-year. The presentation also detailed the company's R&D expenditures, which accounted for 10.9% of consolidated operating revenue, and emphasized the importance of R&D in driving future revenue. Additionally, management discussed recent product approvals and the successful acquisition of a USFDA-approved manufacturing facility in New Jersey, aimed at enhancing production capabilities. The document concluded with a focus on leadership changes to support growth.
Management emphasized strong financial growth and strategic acquisitions.
Sourced from an exchange-filed presentation, dated 14 Aug 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Rubicon Research Limited's investor presentation dated August 14, 2026, provided a comprehensive overview of the company's financial performance for Q1 FY 2026-27. The presentation reported a 51.6% year-on-year increase in revenue from operations, amounting to ₹5,343 million, with EBITDA rising to ₹1,312 million. The company highlighted the impact of the Arinna acquisition, contributing ₹128 million to revenue. Management noted a stable pricing environment and strong revenue visibility, with USD revenue reaching $55 million, up 32% year-on-year. The presentation also detailed the company's R&D expenditures, which accounted for 10.9% of consolidated operating revenue, and emphasized the importance of R&D in driving future revenue. Additionally, management discussed recent product approvals and the successful acquisition of a USFDA-approved manufacturing facility in New Jersey, aimed at enhancing production capabilities. The document concluded with a focus on leadership changes to support growth.
Management emphasized strong financial growth and strategic acquisitions.
Sourced from an exchange-filed presentation, dated 14 Aug 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Rubicon Research Limited's investor presentation dated May 29, 2026, provided a comprehensive overview of the company's financial performance for Q4 FY 2025-26. The presentation reported a revenue from operations of ₹5,139 million, reflecting a year-on-year growth of 43.5%. EBITDA for the quarter was ₹1,213 million, up 67.2% from the previous year, with a PAT of ₹768 million, marking a significant increase of 111.8%. The document highlighted a stable pricing environment and strong revenue visibility, with 92% of approved products commercialized. R&D expenses were noted at 11.6% of operating revenue, with a focus on maintaining R&D productivity. The company also announced a dividend of 150%, amounting to ₹1.50 per share. Additionally, the presentation discussed the strategic acquisition of Arinna Lifesciences and the ongoing development of its specialty product portfolio.
The presentation emphasized strong financial growth and strategic initiatives.
Sourced from an exchange-filed presentation, dated 29 May 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Rubicon Research Limited's investor presentation dated February 3, 2026, provided a comprehensive overview of the company's financial performance for Q3 FY 2025-26. The presentation reported a revenue from operations of ₹4,755 million, reflecting a year-on-year growth of 51.7%. EBITDA for the quarter was ₹1,119 million, up 59.0% from the previous year, with a PAT of ₹728 million, marking a 91.2% increase. The document highlighted a strong cash flow generation culture, with cash flow from operations reported at ₹350 million. Management noted that R&D expenses constituted 11.0% of operating revenue, emphasizing their role in future revenue growth. The company also reported receiving nine product approvals in the first nine months of FY 2026, with a commercialization rate of 93%. The presentation outlined the company's strategic focus on specialty products and a robust pipeline, alongside a commitment to maintaining high R&D productivity.
The presentation emphasized strong financial growth and a robust product pipeline.
Sourced from an exchange-filed presentation, dated 03 Feb 2026. Summary is RedixFi-generated and distinct from investment advice.
AI Summary of Annual Report
AI-generatedRubicon Research Limited's annual report for FY2025-26 highlights its strategic focus on innovation, quality, and care in pharmaceuticals, emphasizing differentiated therapies and global regulatory compliance. The report outlines a robust quality management system aligned with international standards, along with initiatives in employee development, supply chain resilience, and sustainability. The company also discusses its acquisition of Arinna Lifesciences to strengthen its CNS portfolio and expand its commercial platform in India, while maintaining disciplined capital allocation and governance practices.
- Strategic emphasis on innovation, quality, and care in pharmaceuticals with a focus on differentiated therapies and global regulatory compliance.
- Robust quality management system aligned with ICH Q10, EU GMP, and US FDA standards, ensuring product safety and regulatory adherence.
- Acquisition of Arinna Lifesciences to expand CNS portfolio and commercial capabilities in India, aligning with therapeutic expertise and market opportunities.
- Commitment to employee development through Rubicon Academy and structured training programs, enhancing workforce capabilities and retention.
- Management has stated a target of improved pre-tax ROACE to 36% in FY2026.
Key takeaway: Rubicon Research Limited is prioritizing innovation and quality in pharmaceuticals, with a strong focus on differentiated therapies, global regulatory compliance, and strategic acquisitions to expand its CNS portfolio and commercial capabilities in India.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
No item of a kind that needs attention was stored for this company.
Contingent Liability
2 occurrencesRecent (last 12 months)
Rubicon Research Limited has contingent liabilities from pending income tax appeals and performance undertakings related to its subsidiary AdvaGen Pharma Ltd's factoring arrangement.
Rubicon Research Limited has contingent liabilities from pending income tax appeals and performance undertakings related to its subsidiary AdvaGen Pharma Ltd's factoring arrangement.
Related-Party Transaction
2 occurrencesRecent (last 12 months)
Rubicon Research Limited has sales to related parties accounting for 78.87% of total sales in FY 2025-26 and 67.80% in FY 2024. Additionally, the company has 100% of its loans and advances given to related parties and 82.18% of total investments in related parties in FY 2025-26.
Rubicon Research Limited has sales to related parties accounting for 78.87% of total sales in FY 2025-26 and 67.80% in FY 2024. Additionally, the company has 100% of its loans and advances given to related parties and 82.18% of total investments in related parties in FY 2025-26.
Statutory dues in dispute
2 occurrencesRecent (last 12 months)
The company has unpaid statutory dues related to tax and penalties under dispute, with amounts totaling 6.56, 14.26, and 44.41 million INR, pending before various tax authorities for periods up to 2016-17 to 2023-24.
The company has unpaid statutory dues related to tax and penalties under dispute, with amounts totaling 6.56, 14.26, and 44.41 million INR, pending before various tax authorities for periods up to 2016-17 to 2023-24.